Chronic organ-donor shortage has required the acceptance of steatotic livers for
transplantation purposes despite the higher risk of graft dysfunction or nonfunction associated with the cold ischemia-
reperfusion injury. This study evaluated the use of
melatonin as an additive to Institute Georges Lopez (IGL-1)
solution for protecting nonsteatotic and steatotic liver grafts against cold ischemia-
reperfusion injury. In the current investigation, we used an ex vivo isolated perfused rat liver model. Steatotic and nonsteatotic livers were preserved for 24 hr (4°C) in University of Wisconsin or IGL-1 solutions with or without
melatonin, as well as in University of Wisconsin
solution alone. Thereafter, livers were subjected to 2-hr reperfusion (37°C). We assessed hepatic injury (
transaminases) and function [bile production and
sulfobromophthalein (BSP) clearance, vascular resistance], as well as other factors potentially implicated in the high vulnerability of steatotic livers against
ischemia-reperfusion injury (oxidative stress and related inflammatory mediators including
nitric oxide and
cytokines). We also evaluated well-known cytoprotective factors as
hemeoxygenase 1 (HO-1). Fatty livers preserved in
IGL-1 solution enriched with
melatonin showed lower
transaminase levels and higher bile production and BSP clearance when compared to those obtained for livers maintained in
IGL-1 solution alone. A significant diminution of vascular resistance was also observed when
melatonin was added to the
IGL-1 solution. The
melatonin benefits correlated with the generation of
nitric oxide (through constitutive e-NOS activation) and the prevention of oxidative stress and inflammatory
cytokine release including
tumor necrosis factor and
adiponectin, respectively. The addition of
melatonin to
IGL-1 solution improved nonsteatotic and steatotic liver graft preservation, limiting their risk against cold ischemia-
reperfusion injury.